Analyst consensus rating
Neurogene Analyst Rating: none
Direct answer
Neurogene's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $80.43.
Forecast evidence checked September 5, 2026.
Get free Neurogene email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $38.60
- Average price target
- $80.43
- High price target
- $166.00
- Low price target
- $46.00
- Low target gap
- +19.2%
- Target upside
- +108.4%
- High target gap
- +330.1%
- Target range width
- 310.9%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neurogene?
Neurogene has a verified none consensus. The same dataset has an average price target of $80.43.
How far are Neurogene's low and high targets from the recorded price?
The low target implies +19.2%, while the high target implies +330.1%.
How many analysts are included in Neurogene's consensus?
The verified consensus includes 7 analysts.
How is Neurogene's target upside or downside calculated?
The average target of $80.43 is divided by the recorded price of $38.60, then one is subtracted to produce +108.4%. This does not guarantee a future return.
When was Neurogene's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.